Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Increases By 107.8%

Entera Bio Ltd. (NASDAQ:ENTX) saw a significant increase in short interest in June. As of June 30th, there was short interest totaling 332,658 shares, an increase of 107.8% from the June 15th total of 160,118 shares. Approximately 0.8% of the shares of the stock are sold short. Based on an average daily volume of 5,613,473 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Trading of Entera Bio

Several institutional investors have recently added to or reduced their stakes in ENTX. Superstring Capital Management LP bought a new position in shares of Entera Bio during the fourth quarter valued at approximately $33,000. Citadel Advisors LLC lifted its stake in shares of Entera Bio by 243.0% during the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock worth $77,000 after acquiring an additional 28,322 shares during the last quarter. HighTower Advisors LLC boosted its holdings in Entera Bio by 137.8% during the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock valued at $84,000 after acquiring an additional 25,000 shares during the period. Jane Street Group LLC boosted its holdings in Entera Bio by 142.6% during the 4th quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock valued at $144,000 after acquiring an additional 43,536 shares during the period. Finally, Renaissance Technologies LLC grew its position in Entera Bio by 22.2% in the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock valued at $210,000 after acquiring an additional 19,601 shares during the last quarter. Institutional investors own 14.11% of the company’s stock.

Entera Bio Stock Performance

NASDAQ ENTX traded down $0.02 on Friday, hitting $1.98. 66,508 shares of the stock were exchanged, compared to its average volume of 589,835. Entera Bio has a 52-week low of $0.91 and a 52-week high of $3.22. The firm has a market capitalization of $97.64 million, a P/E ratio of -7.34 and a beta of 1.43. The stock has a fifty day moving average price of $1.39 and a two-hundred day moving average price of $1.38.

Entera Bio (NASDAQ:ENTX) last announced its earnings results on Friday, May 8th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01. Sell-side analysts expect that Entera Bio will post -0.34 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ENTX. Weiss Ratings restated a “sell (d-)” rating on shares of Entera Bio in a research report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating on shares of Entera Bio in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $9.00.

About Entera Bio

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.